U.S. weighs new measures for travelers from China as Japan says it will require negative Covid tests

U.S. weighs new measures for travelers from China as Japan says it will require negative Covid tests


For more than two years, overseas travelers have had to quarantine upon arrival in China because of Covid restrictions. Pictured here at Beijing International Airport on June 18, 2022, are passengers waiting to be taken to quarantine-designated destinations.

Leo Ramirez | Afp | Getty Images

The U.S. government is considering imposing new Covid rules for travelers from China, officials said, citing concerns over virus-related data released by the Chinese government.

“There are mounting concerns in the international community on the ongoing COVID-19 surges in China and the lack of transparent data, including viral genomic sequence data, being reported from the PRC,” officials said in a statement late Tuesday.

“Without this data, it is becoming increasingly difficult for public health officials to ensure that they will be able to identify any potential new variants and take prompt measures to reduce the spread,” the officials said.

The officials pointed to Japan’s recent measures which require a negative Covid test for travelers arriving from mainland China from Dec. 30 – as China faces a sharp surge in infections nationwide following an abrupt reopening.

Travelers from China without a valid vaccination certificate will also be required to take a pre-departure test, the notice from Japan’s health ministry added. The measures will not apply to those traveling from Hong Kong and Macao, according to the notice.

Read more about China from CNBC Pro

When asked for comment on Japan’s measures, the Chinese Ministry of Foreign Affairs emphasized a need for a “science-based” measures, without elaborating further.

“The current COVID situation in the world continues to call for a science-based response approach and joint effort to ensure safe cross-border travel, keep global industrial and supply chains stable, and restore world economic growth,” deputy director-general Wang Wenbin told reporters in a Tuesday briefing.

The U.S. officials mentioned Malaysia is also taking measures while India and the World Health Organization have expressed their concern about the situation in China.

“The U.S. is following the science and advice of public health experts, consulting with partners, and considering taking similar steps we can take to protect the American people,” the officials said.

— CNBC’s Evelyn Cheng contributed to this report.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More